Target intelligence / Profile preview

Glucosidase II alpha subunit (GANAB)

Target
GANAB
Molecular classification
Enzyme, Glycosyl hydrolase family 31 (GH31), Retaining α-glycosidase
01

Overview

Glucosidase II alpha subunit (encoded by the GANAB gene) is the catalytic component of a heterodimeric enzyme in the ER responsible for the sequential removal of α1,3-linked glucose residues from N-linked oligosaccharides on glycoproteins. This two-step glucose trimming, accomplished with the β-regulatory subunit, facilitates ER-associated protein folding, quality control, and subsequent transport. Its activity generates a transient protein tag recognized by lectin chaperones like calnexin and calreticulin, promoting proper maturation or facilitating refolding before misfolded proteins are targeted for degradation. Dysregulation or mutation of GANAB is causative of autosomal dominant polycystic kidney and liver disease and may be implicated in cancer and other protein-folding disorders

Other names
GANABGIIαGII alphaNeutral glycosyl hydrolase 31 alpha subunitGlucosidase 2 subunit alpha
02

Mechanism of action

Drugs or inhibitors targeting this molecule act by blocking its catalytic active site and preventing hydrolysis of α1,3-linked glucose residues from N-glycans

03

Biological functions

Protein folding quality controlRemoval of glucose residues from immature glycoproteins in ERER-associated glycoprotein processingEnzymatic hydrolysis of glycosidic bonds
04

Disease associations

Polycystic kidney disease (autosomal-dominant polycystic kidney and liver disease)Cancer (expression elevated in lung tumor tissue)Roles suggested in viral infection pathways (e.g., SARS-CoV-2)
05

Safety considerations

Inhibition or dysregulation of Glucosidase II alpha is associated with defective protein folding and ER stress, leading to potential toxicity, impaired glycoprotein maturation, and development of polycystic kidney/liver diseaseOff-target effects are possible given broad roles in glycoprotein processing
06

Interacting drugs

α-glucosidase inhibitors (e.g., Tris)
07

Biomarkers

Mutations in GANAB are biomarkers for autosomal-dominant polycystic kidney and liver diseaseElevated protein expression may be evaluated as a biomarker in specific cancersNo widely validated clinical biomarker assays found

Beyond the preview

Go deeper on Glucosidase II alpha subunit (GANAB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glucosidase II alpha subunit (GANAB).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call